News & Events

• Servatus Biopharmaceuticals Joins Microbiome Therapeutics Innovation Group
  Published on 2021-03-29
• Seres Therapeutics to Present at the 31st Annual Oppenheimer Healthcare Conference
  Published on 2021-03-12
• Seres Therapeutics Announces Discontinuation of Enrollment in SER-401 Study in Metastatic Melanoma
  Published on 2021-03-08
• Microba Life Sciences joins Microbiome Therapeutics Group
  Published on 2021-03-04
• Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis
  Published on 2021-03-02
• Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates
  Published on 2021-03-02
• Vedanta Biosciences to Present at Upcoming Investor Conferences
  Published on 2021-03-02
• Seres Therapeutics to Host Fourth Quarter 2020 Financial Results and Operational Progress Conference Call on March 2, 2021
  Published on 2021-02-24
• Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer
  Published on 2021-02-08
• Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium
  Published on 2021-01-19
• Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.
  Published on 2021-01-12
• Seres Therapeutics Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal Gastroenterology
  Published on 2021-01-06
• Seres Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
  Published on 2021-01-06
• Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors
  Published on 2020-11-24
• Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences
  Published on 2020-11-19